Rudolf K, Eberlein W, Engel W, Wieland H A, Willim K D, Entzeroth M, Wienen W, Beck-Sickinger A G, Doods H N
Division of Pharma Research, Dr. Karl Thomae GmbH, Biberach, Germany.
Eur J Pharmacol. 1994 Dec 27;271(2-3):R11-3. doi: 10.1016/0014-2999(94)90822-2.
The design and subsequent in vitro and in vivo biological characterisation of the first potent and selective non-peptide neuropeptide Y Y1 receptor antagonist, BIBP3226 ((R)-N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-argininami de) is reported. BIBP3226 displaced 125I-labelled neuropeptide Y with high affinity (Ki = 7 nM) from the human neuropeptide Y Y1 receptor and proved to be highly selective. BIBP3226 displayed potent antagonistic properties both in in vitro and in vivo models and thus represents the first selective non-peptide neuropeptide Y Y1 receptor antagonist.
本文报道了首个强效、选择性非肽类神经肽Y Y1受体拮抗剂BIBP3226((R)-N2-(二苯基乙酰基)-N-[(4-羟基苯基)甲基]-精氨酰胺)的设计及其后续的体外和体内生物学特性研究。BIBP3226能以高亲和力(Ki = 7 nM)从人神经肽Y Y1受体上取代125I标记的神经肽Y,且具有高度选择性。BIBP3226在体外和体内模型中均表现出强效的拮抗特性,因此是首个选择性非肽类神经肽Y Y1受体拮抗剂。